Re: Stifel View
Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer and sarcoma.[1][2] Although results of phase I and early phase II trials showed promise, research for these indications were discontinued in 2009 by Roche. Phase II trials still in progress were allowed to complete, as the development was halted due to business prioritization rather than safety concerns.
The above is from Wikipedia, but shows that T was originally developed for other purposes. Should A pan out in combo therapies, T will quickly join the new Oncology department with lots of potential for additional payoffs!